Status:
UNKNOWN
Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma
Lead Sponsor:
Scripps Clinic
Conditions:
Asthma
Allergic Rhinitis
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Double blind protocol treatment of 2/3 of the patients with omalizumab and 1/3 placebo administer for 4 months. Patients selected for the study must have both aspirin exacerbated respiratory disease a...
Detailed Description
60 patients with Aspirin Exacerbated respiratory Disease will be screened to determine if they also have allergic respiratory tract disease as a co-morbid complication. This will involve history, alle...
Eligibility Criteria
Inclusion
- aspirin exacerbated respiratory disease and allergic asthma
Exclusion
- pregnant females,starting immunotherapy in the past 3 months, prior treatment with Xolair, negative allergy skin tests,unable to participate in lung function tests, unable to complete data forms,low platelets, serum IGE greater than 700 iu,cancer,another uncontrolled medical condition, unacceptable concomitant medication, under the age of 18 years.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
July 1 2008
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00286416
Start Date
January 1 2006
End Date
July 1 2008
Last Update
November 7 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Scripps Clinic at Torrey Pines
La Jolla, California, United States, 92037